A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants With Major Depressive Disorder (MDD)
Latest Information Update: 05 Feb 2025
Price :
$35 *
At a glance
- Drugs JNJ-89495120 (Primary)
- Indications Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development
- 29 Jan 2025 New trial record